ClinicalTrials.gg
RecruitingNCT06754098Updated Sep 17, 2026

Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency

A Phase 2 interventional study of Doxecitine and Doxribtimine in Thymidine Kinase 2 (TK2 ) Deficiency and Mitochondrial Myopathies, sponsored by Cristina Domínguez González. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Cristina Domínguez González · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to evaluate the efficacy and safety of Doxecitin and Doxribtimine (dC+dT) in adult participants with thymidine kinase 2 (TK2) deficiency attended in the Neuromuscular Unit of '12 de Octubre' Hospital.

The main questions it aims to answer are:

  • Is dT+dC effective in the treatment of the adult participants with TK2 deficiency?
  • Is dT+dC safe in the treatment of adult participants with TK2 deficiency?

Researchers will evaluate the effectiveness of the treatment doxecitin and doxribthymine in adult participants with TK2 deficiency. In addition, the mitochondrial DNA levels before and after treatment (extracted from the muscle and from uroepithelial cells) of these participants will be also studied.

Read the detailed description

This is an Open Label, single-arm, single-center clinical study to evaluate the efficacy and safety of dT+dC in adults with TK2 deficiency (TK2d). TK2 deficiency is one of several mitochondrial autosomal recessive disorders that are collectively referred to as mitochondrial DNA depletion and multiple deletions syndromes (MDDS), in fact, TK2d is an ultra-rare disease, presenting as progressive proximal muscle weakness in all patients; however, clinical presentations are heterogeneous in nature and manifest with variable levels of severity and functional impairment across patients.

The study seeks to enroll patients under follow-up in the Neuromuscular Unit of '12 de Octubre' Hospital. All participants will be required to attend a screening visit at which their eligibility for the study will be determined. After signing the informed consent and verifying that they met all inclusion and exclusion criteria, participants will receive a daily dose of dT+dC in 3 equal divided doses administered orally at an approximate interval of 6 (±2) hours. dT+dC is to be initially dosed (commencing on Day 1) at 130 mg/kg/day of each nucleoside (130 mg/kg/day dC and 130 mg/kg/day dT), divided into 3 equal daily doses of approximately 43 mg/kg/dose. If the tolerability profile is acceptable after 2 weeks (approximately Day 15), the dose is to be increased to 260 mg/kg/day of each nucleoside (approximately 86 mg/kg/dose three-times daily, (TID). If the tolerability profile remains acceptable after an additional 2 weeks of dosing (approximately Day 29) the dose is to be further increased to 400 mg/kg/day (approximately 133 mg/kg/dose TID). The maximum dose is 400 mg/kg/day. The tolerability profile of the treatment will be evaluated based on whether the patient has diarrhea.

The total number of participants for the safety and efficacy analysis will be 10 to 15 participants with progressive myopathy with respiratory involvement.

The estimated duration of the study for individual participants will be 24 months. Although, based on previous experience in treating these patients, the investigators expect to see results within the first 6 to 12 months of treatment.

It is hypothesized that dT+dC oral administration is safe, well tolerated and clinically beneficial in adults with TK2 deficiency.

02

Conditions studied

  • Thymidine Kinase 2 (TK2 ) Deficiency
  • Mitochondrial Myopathies

Keywords

  • TK2 deficiency
  • Primary Mitochondrial Myopathy
  • Deoxycytidine (dC)
  • Deoxythymidine (dT)
  • Mitochondrial DNA depletion and multiple deletions syndromes (MDDS)
03

In context

Mitochondrial Myopathies

46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.

This study's planned enrollment of 15 is below the median of 24 across 31 interventional studies indexed under Mitochondrial Myopathies.

Browse Mitochondrial Myopathies studies →

Lead sponsor

Cristina Domínguez González is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed by the subject.
  2. Subject must be greater than 18 years of age at time of consent.
  3. Genetic diagnosis of TK2 deficiency
  4. Subject should have evidence of a moderate to severe disease, with motor and or respiratory involvement, shown by one of the following:

    1. North Star Ambulatory Assessment Scale (NSAA) less than 30
    2. 6-minute walking test less than 450 meters
    3. Force Vital Capacity in the sitting position less than 70 percent or a drop in the decubitus position greater than 10 percent or need for mechanical ventilation.
    4. Disabling symptoms and evidence of motor and/or respiratory function progressive decline.
  5. Female subjects must have no intention to become pregnant during the study. Female subjects who are of (that is, following menarche until at least 1 year if not anatomically and physiologically incapable of becoming pregnant) must agree and commit to the use of highly effective methods of for the duration of the study and for 30 days after the end of the study, and be willing to have additional pregnancy tests conducted during the study. Acceptable methods are defined as those that result, alone or in combination, in a low failure rate (that is, less than 1 percent per year) when used consistently and correctly, such as surgical sterilization, an intrauterine device, or hormonal contraception in combination with a barrier method.
  6. Male subjects with partners of childbearing potential must agree to use effective contraception methods during the study and for at least 90 days after the last dose of the study medication. Acceptable methods include the use of condoms combined with spermicidal foam/gel/film/cream/suppository.
  7. Willingness to comply with the study protocol, including but not limited to, all study procedures, study visits, and study drug compliance.

Exclusion criteria

Exclusion Criteria:

  1. History of liver disease, or liver function test results ( [ALT], aspartate transaminase [AST], or total ) greater than or equal2 times (2X) the . Patients with transaminases greater than 2 times (2X) can participate with the approval and monitoring of a doctor specializing in liver toxicity.
  2. Participation in a previous trial of any agent for primary mitochondrial disease within 1 year prior to , or use of any other investigational therapy within 30 days (or 3 half-lives, whichever is longer) prior to informed consent, or participation in other clinical studies, within 30 days prior to informed consent, which in the opinion of the study Sponsor, may potentially confound results from this study.
  3. Pregnant (females 10.0 years old or older will have a pregnancy test at screening), or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    doxecitin and doxribthymine (dT+dC)

    This is an open label study with all participants in a single arm. Study participants will take doxecitine and doxribtimine up to a maximum of 800 mg/kg/day (400 mg/kg/day doxecitine and 400 mg/kg/day doxiribtimine).

    Drug: Doxecitine and Doxribtimine

Interventions

  • DrugDoxecitine and Doxribtimine

    A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.

06

What researchers measure

Primary outcomes

  1. Efficacy - Motor Function Assessments: Neurological Exam using Medical Research Council (MRC Scale) Scale for Muscle Strength

    Motor Function will be measured using the MRC scale. The scale provides a measure of Muscle Strength across a range from 0 (No visible muscle contraction) to 5 (Full strength)

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  2. Efficacy - Motor Function Assessments: 6-minute walk test

    Motor Function will be measured using the 6-minute walk test (6MWT). Distance walked in meters over 6 minutes will be measured

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  3. Efficacy - Motor Function Assessments: North Star Ambulatory Assessment (NSAA)

    Motor function will be assessed using the NSAA scale. The NSAA is a 17-item scale that grades performance of various functional activities on a scale graded 0 (unable to complete the activity), 1 (completes the activity independently but with modifications), and 2 (completes the activity without modifications)

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  4. Efficacy - Motor Function Assessments: 100 meter-time velocity test

    Time to run 100 meters measured in seconds (sec)

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  5. Efficacy - Motor Function Assessments: Fatigue Scale test

    Motor function will be assessed Fatigue Scale test. The FACIT-Fatigue is a 13-item patient-reported outcome measure (range from 0 to 52: 0 = very much fatigued, 52 = not at all fatigued) assessing fatigue over the previous week

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  6. Efficacy - Respiratory Assessments measured by spirometry

    * Sitting Forced Vital Capacity (Sitting FVC) measure in percentage (%) * Drop in FVC lying down measured in percentage (%) * Maximal Inspiratory Pressure (MIP) measure in percentage: Evaluation of the strength of respiratory muscles is performed with measurements of MIP expressed in percentage (%) * Maximal Inspiratory Pressure (MEP) measure in percentage: Evaluation of the strength of respiratory muscles is performed with measurements of MEP expressed in percentage (%)

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  7. Efficacy - Respiratory Assessments: Use of ventilatory support (Use and Type )

    Use and Type of mechanical ventilation (MV) \[bilevel positive airway pressure (BiPAP) and/or continuous positive airway pressure (CPAP)\] per subject will be assessed

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  8. Efficacy - Respiratory Assessments: Time of use of ventilatory support

    Total of hours of use of mechanical ventilation (MV) per subject will be assessed

    Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24

  9. Serum Biomarkers: lactate levels

    Number of participants with normal vs abnormal lactate levels measured in mmol/l

    Time frame: Up to 24 months

  10. Serum Biomarkers: Growth/differentiation factor-15 (GDF15 )

    Number of participants with normal vs abnormal Growth/differentiation factor-15 (GDF15) levels measured in mmol/l compared to normal ranges

    Time frame: Up to 24 months

Secondary outcomes

  1. Safety as adverse events (AEs)

    Number of participants who experience adverse events (AEs)

    Time frame: Up to 24 months

  2. Safety as serious adverse events (SAEs)adverse events

    Number of participants who experience serious adverse events (SAEs)

    Time frame: Up to 24 months

Other outcomes

  1. Changes in the mtDNA levels before and after treatment

    To assess change in mitochondrial DNA (mtDNA) levels, a muscle biopsy with a needle will be performed before entering the study and 6 months after the start of treatment

    Time frame: 6 month

  2. Changes in the peak oxygen consumption (VO2 max) test

    A progressive exercise test will be undertaken at screening to assess peak oxygen consumption (VO2 max) using an electronically braked recumbent cycle ergometer.

    Time frame: 6 month

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Dominguez-Gonzalez C, Badosa C, Madruga-Garrido M, Marti I, Paradas C, Ortez C, Diaz-Manera J, Berardo A, Alonso-Perez J, Trifunov S, Cuadras D, Kalko SG, Blazquez-Bermejo C, Camara Y, Marti R, Mavillard F, Martin MA, Montoya J, Ruiz-Pesini E, Villarroya J, Montero R, Villarroya F, Artuch R, Hirano M, Nascimento A, Jimenez-Mallebrera C. Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy. Sci Rep. 2020 Jun 22;10(1):10111. doi: 10.1038/s41598-020-66940-8. PubMed 32572108 ↗
  • Berardo A, Dominguez-Gonzalez C, Engelstad K, Hirano M. Advances in Thymidine Kinase 2 Deficiency: Clinical Aspects, Translational Progress, and Emerging Therapies. J Neuromuscul Dis. 2022;9(2):225-235. doi: 10.3233/JND-210786. PubMed 35094997 ↗
  • Bermejo-Guerrero L, Hernandez-Voth A, Serrano-Lorenzo P, Blazquez A, Martin-Jimenez P, Martin MA, Dominguez-Gonzalez C. Remarkable clinical improvement with oral nucleoside treatment in a patient with adult-onset TK2 deficiency: A case report. Mitochondrion. 2024 May;76:101879. doi: 10.1016/j.mito.2024.101879. Epub 2024 Apr 9. PubMed 38599303 ↗
  • Dominguez-Gonzalez C, Madruga-Garrido M, Mavillard F, Garone C, Aguirre-Rodriguez FJ, Donati MA, Kleinsteuber K, Marti I, Martin-Hernandez E, Morealejo-Aycinena JP, Munell F, Nascimento A, Kalko SG, Sardina MD, Alvarez Del Vayo C, Serrano O, Long Y, Tu Y, Levin B, Thompson JLP, Engelstad K, Uddin J, Torres-Torronteras J, Jimenez-Mallebrera C, Marti R, Paradas C, Hirano M. Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy. Ann Neurol. 2019 Aug;86(2):293-303. doi: 10.1002/ana.25506. Epub 2019 Jun 17. PubMed 31125140 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2024
First posted
Dec 31, 2024
StartActual
Jan 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06754098
Lead sponsor
Cristina Domínguez González
Collaborators
UCB Pharma
Responsible party
Cristina Domínguez González (Doctor, Hospital Universitario 12 de Octubre) — Sponsor-investigator
First posted
Dec 31, 2024
Start date
Jan 1, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Cristina Domínguez González, Dra.
Contact
cdgonzalez@salud.madrid.org
+34 917792582
Cristina D Domínguez González, Dra.
principal investigator · Hospital 12 de Octubre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion